New hope for heart failure: can a simple valve fix keep patients out of the hospital?
NCT ID NCT04634266
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a minimally invasive procedure to repair a leaky tricuspid valve can help people with right-sided heart failure. About 360 participants will either receive the valve repair plus standard medications or medications alone. The goal is to see if the repair reduces deaths, hospitalizations, and improves quality of life over one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
transcatheter tricuspid valve repair devices (annuloplasty or edge-to-edge repair)
What this could lead to
If successful, this could provide a proven treatment option to reduce hospitalizations and improve survival for people with severe tricuspid regurgitation and right-sided heart failure.
What could go wrong
This is a mid-stage trial with 360 participants, so results may not apply to all patients. The procedure carries risks like bleeding or device complications, and it is unclear if it will meaningfully improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE ATTRIBUTABLE TO SEVERE TRICUSPID REGURGITATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asklepios Klinikum St. Georg
Hamburg, Germany
-
Charité Universitätsmedizin Berlin
Berlin, Germany
-
Deutsches Herzzentrum Berlin
Berlin, Germany
-
Helios Klinikum Erfurt
Erfurt, Germany
-
Helios Klinikum Wuppertal
Wuppertal, Germany
-
Herz- und Diabeteszentrum Nordrhein-Westfalen
Bad Oeynhausen, Germany
-
Herzentrum Leipzig
Leipzig, Germany
-
Herzzentrum Bremen
Bremen, Germany
-
Herzzentrum Siegburg
Siegburg, Germany
-
Herzzentrum UKE
Hamburg, Germany
-
Herzzentrum Uniklinik Köln
Cologne, Germany
-
Immanuel Klinikum Bernau Herzzentrum Brandenburg
Bernau, Germany
-
Katholisches Marienkrankenhaus Hamburg
Hamburg, Germany
-
LMU Klinikum
München, Germany
-
Robert Bosch Klinikum Stuttgart
Stuttgart, Germany
-
St.-Johannes-Hospital Dortmund
Dortmund, Germany
-
Universitätsklinikum Bonn
Bonn, Germany
-
Universitätsklinikum Düsseldorf
Düsseldorf, Germany
-
Universitätsklinikum Essen
Essen, Germany
-
Universitätsklinikum Frankfurt
Frankfurt, Germany
-
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
-
Universitätsklinikum Heidelberg
Heidelberg, Germany
-
Universitätsklinikum Jena
Jena, Germany
-
Universitätsklinikum Schleswig-Holstein
Kiel, Germany
-
Universitätsklinikum Schlewsig-Holstein Campus Lübeck
Lübeck, Germany
-
Universitätsklinikum Tübingen
Tübingen, Germany
-
Universitätsklinikum Ulm
Ulm, Germany
-
Universitätsmedizin Mainz
Mainz, Germany